Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on the strengths of OTC medicines. While touching on pertinent topics that affect the entire pharmaceutical production value chain, Costa highlights the favorable investment climate we see in Portuguese healthcare today, and the recent success in both approval times and reimbursements for innovative drugs.
Can you provide our international readers with an overview of APIFARMA’s current standing in Portugal?
"The government has approved more innovative medicines in the past two years than the combined total reached during the period from 2010-2015; roughly 60 in 2017 and 51 in 2016."
